WHO gives emergency use listing to Moderna's COVID-19 vaccine

Reuters2021-05-01

ZURICH, April 30 (Reuters) - The World Health Organization has listed Moderna's COVID-19 vaccine for emergency use, the agency said on Friday, the fifth to be given the status meant to expedite countries' own approval of shots.

"The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency," the WHO said in a statement.

WHO Assistant Director-General Mariangela Simao said on Friday it was important to have more vaccines available because of supply problems for other shots, including from India, a main source of vaccines for the global COVAX vaccine sharing programme. India has restricted exports because of a crisis of infections.

Moderna announced this week an expansion plan for its production network to boost its capacity to up to 3 billion doses in 2022.

The WHO's Strategic Advisory Group of Experts on Immunization $(SAGE)$ already in January had recommended Moderna's vaccine for all age groups 18 and above.

Pfizer and its German partner BionTech's shot, also an mRNA vaccine like Moderna's, was the first vaccine to get a WHO emergency use listing in the final hours of 2020.

Since then, the WHO has added vaccines from Astrazeneca-SK Bio, Serum Institute of India and Johnson & Johnson vaccines to the list.

The Geneva-based health organization is still considering COVID-19 vaccines from Sinopharm and Sinovac following an extended review, with decisions due by the end of next week.

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ GRAPHIC-COVID-19 Vaccination Tracker

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

(Reporting by John Miller; editing by Grant McCool)

((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • HLPA
    2021-05-01
    HLPA
    Approval for BB Covaxin?
  • wygoh99
    2021-05-01
    wygoh99
    My bro use moderna in Singapore
Leave a comment
2